Skip to main content
. 2021 May 28;14:17562848211016959. doi: 10.1177/17562848211016959

Figure 3.

Figure 3.

Several TME components promote an immune suppressive environment. Regorafenib may modulate an immune-suppressive TME and promote anti-tumor immunity, blocking VEGFRs, TIE2, and CSF-1R.

CTL, cytotoxic T lymphocyte; CSF-1R, colony-stimulating factor 1 receptor; DC, Dendric cells; EC, endothelial cell; TAM, tumor-associated macrophages; TEM, TIE2-expressing monocyte/macrophages; TME, tumor microenvironment; Treg, regulatory T cells; VEGFRs, vascular endothelial growth factor receptors.